Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/14/2025 | $18.00 | Buy | UBS |
1/29/2024 | $10.00 → $17.00 | Equal Weight → Overweight | Barclays |
10/20/2023 | $5.00 → $10.00 | Sell → Neutral | Citigroup |
9/21/2023 | $10.00 | Equal Weight | Barclays |
9/7/2022 | $10.00 | Equal-Weight | Morgan Stanley |
9/6/2022 | $12.00 → $5.00 | Buy → Sell | Citigroup |
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:
6-K - Alvotech (0001898416) (Filer)
6-K - Alvotech (0001898416) (Filer)
6-K - Alvotech (0001898416) (Filer)
UBS initiated coverage of Alvotech with a rating of Buy and set a new price target of $18.00
Barclays upgraded Alvotech from Equal Weight to Overweight and set a new price target of $17.00 from $10.00 previously
Citigroup upgraded Alvotech from Sell to Neutral and set a new price target of $10.00 from $5.00 previously